|
[1] KITADE H,CHEN G,NI Y,et al. Nonalcoholic fatty liver disease and insulin resistance:New insights and potential new treatments[J]. Nutrients,2017,9(4):387.
|
|
[2] JIANG M,WU N,CHEN X,et al. Pathogenesis of and major animal models used for nonalcoholic fatty liver disease[J]. J Int Med Res,2019,47(4):1453-1466.
|
|
[3] WONG VW,CHITTURI S,WONG GL,et al. Pathogenesis and novel treatment options for non-alcoholic steatohepatitis[J].Lancet Gastroenterol Hepatol,2016,1(1):56-67.
|
|
[4] LIU TY,XIONG XQ,REN XS,et al. FNDC5 alleviates hepatosteatosis by restoring AMPK/m TOR-mediated autophagy,fatty acid oxidation,and lipogenesis in mice[J]. Diabetes,2016,65(11):3262-3275.
|
|
[5] GUHA P,TYAGI R,CHOWDHURY S,et al. IPMK mediates activation of ULK signaling and transcriptional regulation of autophagy linked to liver inflammation and regeneration[J]. Cell Rep,2019,26(10):2692-2703.
|
|
[6] GUHA P,SNYDER SH. Noncatalytic functions of IPMK are essential for activation of autophagy and liver regeneration[J].Autophagy,2019,15(8):1473-1474.
|
|
[7] SHI C,XUE W,HAN B,et al. Acetaminophen aggravates fat accumulation in NAFLD by inhibiting autophagy via the AMPK/m TOR pathway[J]. Eur J Pharmacol,2019,850:15-22.
|
|
[8] ZHANG S,MAO Y,FAN X. Inhibition of ghrelin o-acyltransferase attenuated lipotoxicity by inducing autophagy via AMPKm TOR pathway[J]. Drug Des Devel Ther,2018,12:873-885.
|
|
[9] SHI J,FAN J,SU Q,et al. Cytokines and abnormal glucose and lipid metabolism[J]. Front Endocrinol(Lausanne),2019,10:703.
|
|
[10] JUNG TW,YOO HJ,CHOI KM. Implication of hepatokines in metabolic disorders and cardiovascular diseases[J]. BBA Clin,2016,5:108-113.
|
|
[11] KE Y,XU C,LIN J,et al. Role of hepatokines in non-alcoholic fatty liver disease[J]. J Transl Int Med,2019,7(4):143-148.
|
|
[12] MISU H,TAKAMURA T,TAKAYAMA H,et al. A liver-derived secretory protein,selenoprotein P,causes insulin resistance[J]. Cell Metab,2010,12(5):483-495.
|
|
[13] PANG J,XU W,ZHANG X,et al. Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther,2017,46(2):175-182.
|
|
[14] JIN CJ,ENGSTLER AJ,ZIEGENHARDT D,et al. Loss of lipopolysaccharide-binding protein attenuates the development of diet-induced non-alcoholic fatty liver disease in mice[J]. J Gastroenterol Hepatol,2017,32(3):708-715.
|
|
[15] NIGHOT M,AL-SADI R,GUO S,et al. Lipopolysaccharide-induced increase in intestinal epithelial tight permeability is mediated by toll-like receptor 4/myeloid differentiation primary response 88(My D88)activation of myosin light chain kinase expression[J]. Am J Pathol,2017,187(12):2698-2710.
|
|
[16] JI Y,YIN Y,LI Z,et al. Gut microbiota-derived components and metabolites in the progression of non-alcoholic fatty liver disease(NAFLD)[J]. Nutrients,2019,11(8):1712.
|
|
[17] GONZALEZ FJ,JIANG CT,PATTERSON AD. An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease[J]. Gastroenterology,2016,151(5):845-859.
|
|
[18] LIU XZ,XU JX. Research progress on the relationship between intestinal flora and non-alcoholic fatty liver disease[J]. Chin J Gerontol,2019,39(11):2815-2818.(in Chinese)刘晓贞，徐积兄．肠道菌群与非酒精性脂肪肝关系的研究进展[J]．中国老年学杂志，2019,39(11):2815-2818.
|
|
[19] RAU M,REHMAN A,DITTRICH M,et al. Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease[J]. United European Gastroenterol J,2018,6(10):1496-1507.
|
|
[20] ZHOU D,CHEN YW,ZHAO ZH,et al. Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression[J]. Exp Mol Med,2018,50(12):1-12.
|
|
[21] CHENG YP,ZHANG XJ,WANG SC,et al. Research progress on the role of adipose factors in the occurrence and development of non-alcoholic fatty liver disease[J]. Shandong Med J,2019,59(30):98-102.(in Chinese)成艺坪，张秀娟，王思超，等．脂肪因子在非酒精性脂肪肝病发生发展中作用的研究进展[J]．山东医药，2019,59(30):98-102.
|
|
[22] POLYZOS SA,ARONIS KN,KOUNTOURAS J,et al. Circulating leptin in non-alcoholic fatty liver disease:A systematic review and meta-analysis[J]. Diabetologia,2016,59(1):30-43.
|
|
[23] HOSSAIN IA,AKTER S,RAHMAN MK,et al. Gender specific association of serum leptin and insulinemic indices with nonalcoholic fatty liver disease in prediabetic subjects[J]. PLo S One,2015,10(11):e0142165.
|
|
[24] XIE LF,CAI YY,JI LL,et al. Research progress of microRNAs in nonalcoholic fatty liver disease[J]. J Pract Med,2016,32(12):2061-2063.(in Chinese)谢璐帆，蔡艳阳，计雷来，等．MicroRNAs在非酒精性脂肪肝中的研究进展[J]．实用医学杂志，2016,32(12):2061-2063.
|
|
[25] LAI CY,LIN CY,HSU CC,et al. Liver-directed microRNA-7a depletion induces nonalcoholic fatty liver disease by stabilizing YY1-mediated lipogenic pathways in zebrafish[J]. Biochim Biophys Acta Mol Cell Biol Lipids,2018,1863(8):844-856.
|
|
[26] YUAN X,WANG J,TANG X,et al. Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles[J]. J Transl Med,2015,13:24.
|
|
[27] LETI F,LEGENDRE C,STILL CD,et al. Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells[J]. Transl Res,2017,190:25-39.
|
|
[28] GREENBERG AS,COLEMAN RA,KRAEMER FB,et al. The role of lipid droplets in metabolic disease in rodents and humans[J]. J Clin Invest,2011,121(6):2102-2110.
|
|
[29] FUJII H,IKURA Y,ARIMOTO J,et al. Expression of perilipin and adipophilin in nonalcoholic fatty liver disease; relevance to oxidative injury and hepatocyte ballooning[J]. J Atheroscler Thromb,2009,16(6):893-901.
|
|
[30] LI JZ,YE J,XUE B,et al. Cideb regulates diet-induced obesity,liver steatosis,and insulin sensitivity by controlling lipogenesis and fatty acid oxidation[J]. Diabetes,2007,56(10):2523-2532.
|
|
[31] CRUNK AE,MONKS J,MURAKAMI A,et al. Dynamic regulation of hepatic lipid droplet properties by diet[J]. PLo S One,2013,8(7):e67631.
|
|
[32] ROMEO S,KOZLITINA J,XING C,et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease[J]. Nat Genet,2008,40(12):1461-1465.
|
|
[33] MARCHISELLO S,DI PINO A,SCICALI R,et al. Pathophysiological,molecular and therapeutic issues of nonalcoholic fatty liver disease:An overview[J]. Int J Mol Sci,2019,20(8):1948.
|
|
[34] SMAGRIS E,BASURAY S,LI J,et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis[J]. Hepatology,2015,61(1):108-118.
|
|
[35] SU W,WANG Y,JIA X,et al. Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease[J]. Proc Natl Acad Sci U S A,2014,111(31):11437-11442.
|
|
[36] HORIGUCHI Y,ARAKI M,MOTOJIMA K. 17beta-Hydroxysteroid dehydrogenase type 13 is a liver-specific lipid droplet-associated protein[J]. Biochem Biophys Res Commun,2008,370(2):235-238.
|
|
[37] TULKENS J,VERGAUWEN G,van DEUN J,et al. Increased levels of systemic LPS-positive bacterial extracellular vesicles in patients with intestinal barrier dysfunction[J]. Gut,2020,69(1):191-193.
|
|
[38] GU L,MENG R,TANG Y,et al. Tol-like receptor 4 signaling licenses the cytosolic transport of lipopolysaccharide from bacterial outer membrane vesicles[J]. Shock,2019,51(2):256-265.
|
|
[39] GARZETTI L,MENON R,FINARDI A,et al. Activated macrophages release microvesicles containing polarized M1 or M2mRNAs[J]. J Leukoc Biol,2014,95(5):817-825.
|
|
[40] BALA S,PETRASEK J,MUNDKUR S,et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic,drug-induced,and inflammatory liver diseases[J]. Hepatology,2012,56(5):1946-1957.
|
DownLoad: